

්ති Schering-Plough

Meeting at Theranos Headquarters 3200 Hillview Avenue, Palo Alto, California 5 May 2009 8:00 a.m. - 5:00 p.m.

8:00 a.m. Light breakfast and introductions

8:30 a.m. Background on Theranos, Inc.

Theranos Point-of-Care Systems – questions from Schering-Plough 9:15 a.m.

1. Assay development and validation

Development process (including proprietary drug level and antibodies assays)

Multiplexing process

Validation process

Validation program timing

Incurred sample reanalysis

2. Quality

Confidentiality & HIPAA compliance

3. Software validation - ensuring result integrity

10:45a Break

11:00 a.m. Theranos Operating System

1. Data Integration

2. Modeling and Simulation

12:15 p.m. Lunch

Conference call connected - (866) 642-1665, Participant code: 864089

Customized Inflammation and Rheumatoid Arthritis System for Schering-Plough

1. Software customization, validation, installation, and self-learning

2. Deployment of monitoring systems

2:30 p.m. Theranos Case Studies

1. Accelerating study timelines

2. Rapid label optimization and expansion pre-approval and in post-marketing studies

3:45 p.m. Break

4:00 p.m. Tour

4:30 p.m. Discussion and action items

Schering-Plough Participants

Malaz Abutarif, Ph.D., G.C.P.M, M.B.A. - Principal Scientist - PK PD and PM group Egbert Biesheuvel, Ph.D. - Statistics Constance Cullen, Ph.D. – Director, Preclinical & Clinical bioanalytics Ferdous Gheyas, Ph.D. - Associate Director, Statistics Jim McLeod - by phone? Mark Watson, M.D., Ph.D. - Director for ECREM Bart van Hoogstraten, M.D., Ph.D. - Director, Global Clinical Research

Theranos Participants

Gary Frenzel - Vice President, Assay Development Ian Gibbons, PhD - Senior Director, Assay Development Elizabeth Holmes - President & CEO Tim Kemp – Theranos Fellow Seth Michelson, MA, MS, PhD - Principal Scientist, Biomathematician Marc Thibonnier, MD, MSc, FAHA - Chief Medical Officer Daniel Young, PhD - Senior Modeler

THERANOS CONFIDENTIAL